[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100515081":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":29,"locations":35,"responsibleParty":131,"collaborators":28,"id":133,"slug":28,"hasResults":134,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":28,"eligibilityCriteria":138,"healthyVolunteers":134,"sex":139,"minAge":140,"maxAge":28,"enrollmentInfo":141,"targetDuration":28,"studyType":144,"phases":145,"briefSummary":148,"conditions":149,"keywords":151,"overallStatus":51,"whyStopped":28,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":166},{"fullName":5,"class":6},"Skyline Therapeutics","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Phase I: Low dose","EXPERIMENTAL","SKG0106 One-Time Intraocular Injection Dose Level 1",[13],"Genetic: SKG0106",{"label":15,"type":10,"description":16,"interventionNames":17},"Phase I: Medium dose","SKG0106 One-Time Intraocular Injection Dose Level 2",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Phase I: High dose","SKG0106 One-Time Intraocular Injection Dose Level 3",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"GENETIC","SKG0106","SKG0106 is a recombinant adeno-associated virus (AAV) vector-based in vivo gene therapeutic product",[19,9,15],null,[30],{"name":31,"role":32,"phone":33,"phoneExt":28,"email":34},"Yongqin Wang","CONTACT","+86 18616737445","yongqin.wang@skytx.com",[36,49,60,76,91,101,110,118,126],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":28},"Retina Vitreous Associates of Florida - Saint Petersburg","NOT_YET_RECRUITING","St. Petersburg","Florida","33711","United States",{"type":44,"coordinates":45},"Point",[46,47],-82.67927,27.77086,{"lat":47,"lon":46},{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":42,"cosmosGeoPoint":55,"geoPoint":59,"contacts":28},"Ophthalmic Consultants of Boston","RECRUITING","Boston","Massachusetts","02114",{"type":44,"coordinates":56},[57,58],-71.05977,42.35843,{"lat":58,"lon":57},{"facility":61,"status":51,"city":62,"state":63,"zip":64,"country":42,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"Retina Consultants of Texas","Katy","Texas","77494",{"type":44,"coordinates":66},[67,68],-95.8244,29.78579,{"lat":68,"lon":67},[71,73],{"name":72,"role":32,"phone":28,"phoneExt":28,"email":28},"Marie Chin",{"name":74,"role":75,"phone":28,"phoneExt":28,"email":28},"Charles C Wykoff, MD","PRINCIPAL_INVESTIGATOR",{"facility":77,"status":51,"city":78,"state":79,"zip":80,"country":42,"cosmosGeoPoint":81,"geoPoint":85,"contacts":86},"Wagner Kapoor Research Institute","Norfolk","Virginia","23502",{"type":44,"coordinates":82},[83,84],-76.28522,36.84681,{"lat":84,"lon":83},[87,89],{"name":88,"role":32,"phone":28,"phoneExt":28,"email":28},"Chris Riebling",{"name":90,"role":75,"phone":28,"phoneExt":28,"email":28},"Alan Wagner, MD",{"facility":92,"status":51,"city":93,"state":94,"zip":28,"country":95,"cosmosGeoPoint":96,"geoPoint":100,"contacts":28},"The Second Hospital Of Anhui Medical University","Hefei","Anhui","China",{"type":44,"coordinates":97},[98,99],117.28083,31.86389,{"lat":99,"lon":98},{"facility":102,"status":51,"city":103,"state":104,"zip":28,"country":95,"cosmosGeoPoint":105,"geoPoint":109,"contacts":28},"Zhejiang Provincial People's Hospital","Hangzhou","Zhejiang",{"type":44,"coordinates":106},[107,108],120.16142,30.29365,{"lat":108,"lon":107},{"facility":111,"status":51,"city":112,"state":104,"zip":28,"country":95,"cosmosGeoPoint":113,"geoPoint":117,"contacts":28},"Eye Hospital, WMU (Zhejiang Eye Hospital)","Wenzhou",{"type":44,"coordinates":114},[115,116],120.66682,27.99942,{"lat":116,"lon":115},{"facility":119,"status":51,"city":120,"state":28,"zip":28,"country":95,"cosmosGeoPoint":121,"geoPoint":125,"contacts":28},"Beijing Hospital","Beijing",{"type":44,"coordinates":122},[123,124],116.39723,39.9075,{"lat":124,"lon":123},{"facility":127,"status":51,"city":120,"state":28,"zip":28,"country":95,"cosmosGeoPoint":128,"geoPoint":130,"contacts":28},"Peking Union Medical College Hospital",{"type":44,"coordinates":129},[123,124],{"lat":124,"lon":123},{"type":132,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100515081",false,"NCT05986864","Phase I\u002FII Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)","Phase I\u002FII Study to Evaluate the Safety and Preliminary Efficacy of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)","Inclusion criteria:\n\n1. Voluntary and able to sign a dated ICF prior to any study-related procedures and able to complete the study as required by the protocol;\n2. Aged ≥ 50 years at screening;\n\n   Study Eye:\n3. Diagnosis of nAMD as determined by the PI;\n4. Active CNV lesions secondary to age-related macular degeneration (AMD);\n5. Subjects must have been responsive to anti-VEGF therapy as assessed by the PI prior to study treatment.\n\nExclusion Criteria:\n\n1. Any active intraocular or periocular infection or active intraocular inflammation (e.g., infectious conjunctivitis, keratitis, scleritis, endophthalmitis, infectious blepharitis, uveitis) in the study eye at baseline;\n2. Retinal pigment epithelial tear in the study eye at screening;\n3. Current vitreous hemorrhage in the study eye or history of vitreous hemorrhage within 4 weeks prior to baseline;\n4. Any condition that, in the opinion of the investigator, may limit visual acuity improvement in the study eye;\n5. History of retinal detachment or active retinal detachment in the study eye;\n6. Any prior gene therapy.","ALL","50 Years",{"count":142,"type":143},68,"ESTIMATED","INTERVENTIONAL",[146,147],"PHASE1","PHASE2","This is a phase 1\u002F2 clinical study to evaluate the safety, preliminary efficacy, immunogenicity, and pharmacokinetic (PK) characteristics of SKG0106 in subjects with nAMD. Based on results from the phase 1 dose escalation study, the phase 2 expansion study will be conducted.",[150],"Neovascular Age-related Macular Degeneration",[152,153,154,155],"AMD","wet AMD","wAMD","nAMD","2025-01-08",{"date":158,"type":159},"2025-01-09","ACTUAL",{"date":161,"type":159},"2024-02-23",{"date":163,"type":143},"2026-01-30",{"name":165,"class":6},"Skyline Therapeutics (US) Inc.",9]